TY  - JOUR
AU  - Langen, Karl-Josef
AU  - Galldiks, Norbert
AU  - Mauler, Jörg
AU  - Kocher, Martin
AU  - Filß, Christian Peter
AU  - Stoffels, Gabriele
AU  - Régio Brambilla, Cláudia
AU  - Stegmayr, Carina
AU  - Willuweit, Antje
AU  - Worthoff, Wieland Alexander
AU  - Shah, Nadim Jon
AU  - Lerche, Christoph
AU  - Mottaghy, Felix Manuel
AU  - Lohmann, Philipp
TI  - Hybrid PET/MRI in Cerebral Glioma: Current Status and Perspectives
JO  - Cancers
VL  - 15
IS  - 14
SN  - 2072-6694
CY  - Basel
PB  - MDPI
M1  - FZJ-2023-03010
SP  - 3577 -
PY  - 2023
N1  - „Open access publication funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – 491111487“
AB  - Advanced MRI methods and PET using radiolabelled amino acids provide valuable information, in addition to conventional MR imaging, for brain tumour diagnostics. These methods are particularly helpful in challenging situations such as the differentiation of malignant processes from benign lesions, the identification of non-enhancing glioma subregions, the differentiation of tumour progression from treatment-related changes, and the early assessment of responses to anticancer therapy. The debate over which of the methods is preferable in which situation is ongoing, and has been addressed in numerous studies. Currently, most radiology and nuclear medicine departments perform these examinations independently of each other, leading to multiple examinations for the patient. The advent of hybrid PET/MRI allowed a convergence of the methods, but to date simultaneous imaging has reached little relevance in clinical neuro-oncology. This is partly due to the limited availability of hybrid PET/MRI scanners, but is also due to the fact that PET is a second-line examination in brain tumours. PET is only required in equivocal situations, and the spatial co-registration of PET examinations of the brain to previous MRI is possible without disadvantage. A key factor for the benefit of PET/MRI in neuro-oncology is a multimodal approach that provides decisive improvements in the diagnostics of brain tumours compared with a single modality. This review focuses on studies investigating the diagnostic value of combined amino acid PET and 'advanced' MRI in patients with cerebral gliomas. Available studies suggest that the combination of amino acid PET and advanced MRI improves grading and the histomolecular characterisation of newly diagnosed tumours. Few data are available concerning the delineation of tumour extent. A clear additive diagnostic value of amino acid PET and advanced MRI can be achieved regarding the differentiation of tumour recurrence from treatment-related changes. Here, the PET-guided evaluation of advanced MR methods seems to be helpful. In summary, there is growing evidence that a multimodal approach can achieve decisive improvements in the diagnostics of cerebral gliomas, for which hybrid PET/MRI offers optimal conditions.
LB  - PUB:(DE-HGF)16
C6  - 37509252
UR  - <Go to ISI:>//WOS:001035143600001
DO  - DOI:10.3390/cancers15143577
UR  - https://juser.fz-juelich.de/record/1010199
ER  -